Use of methotrexate in patients with psoriatic arthritis.
Despite a paucity of high quality clinical data, methotrexate (MTX) remains one of the most commonly used medications in the treatment of patients with psoriatic arthritis (PsA). This report addresses mechanistic rationale, available clinical evidence, safety considerations, and a potential research agenda regarding the use of MTX in the management of PsA.
Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, CA 92037-0943, USA.
A
A
Ceponis
A
A
Kavanaugh
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000276:immunology; D001688:Biological Products / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha; D008727:Methotrexate